US4550016A - Composite cytologic counterstain formulation - Google Patents
Composite cytologic counterstain formulation Download PDFInfo
- Publication number
- US4550016A US4550016A US06/429,662 US42966282A US4550016A US 4550016 A US4550016 A US 4550016A US 42966282 A US42966282 A US 42966282A US 4550016 A US4550016 A US 4550016A
- Authority
- US
- United States
- Prior art keywords
- specimen
- aqueous solution
- dye content
- composite
- cytologic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000002131 composite material Substances 0.000 title claims abstract description 14
- 239000000203 mixture Substances 0.000 title claims abstract description 4
- 238000009472 formulation Methods 0.000 title abstract 2
- 238000000034 method Methods 0.000 claims abstract description 32
- 238000010186 staining Methods 0.000 claims abstract description 13
- 238000003745 diagnosis Methods 0.000 claims description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 14
- 239000007864 aqueous solution Substances 0.000 claims description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 9
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 claims description 8
- MPVDXIMFBOLMNW-ISLYRVAYSA-N 7-hydroxy-8-[(E)-phenyldiazenyl]naphthalene-1,3-disulfonic acid Chemical compound OC1=CC=C2C=C(S(O)(=O)=O)C=C(S(O)(=O)=O)C2=C1\N=N\C1=CC=CC=C1 MPVDXIMFBOLMNW-ISLYRVAYSA-N 0.000 claims description 7
- SEACYXSIPDVVMV-UHFFFAOYSA-L eosin Y Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C([O-])=C(Br)C=C21 SEACYXSIPDVVMV-UHFFFAOYSA-L 0.000 claims description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 6
- DGOBMKYRQHEFGQ-UHFFFAOYSA-L acid green 5 Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 DGOBMKYRQHEFGQ-UHFFFAOYSA-L 0.000 claims description 5
- 229940051132 light green sf yellowish Drugs 0.000 claims description 5
- 229960000583 acetic acid Drugs 0.000 claims description 3
- 239000012362 glacial acetic acid Substances 0.000 claims description 3
- 230000000887 hydrating effect Effects 0.000 claims description 3
- IYDGMDWEHDFVQI-UHFFFAOYSA-N phosphoric acid;trioxotungsten Chemical compound O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.OP(O)(O)=O IYDGMDWEHDFVQI-UHFFFAOYSA-N 0.000 claims description 3
- 239000000243 solution Substances 0.000 claims description 3
- 230000002380 cytological effect Effects 0.000 claims description 2
- 210000005260 human cell Anatomy 0.000 claims description 2
- 235000019441 ethanol Nutrition 0.000 claims 3
- 125000005909 ethyl alcohol group Chemical group 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 230000000007 visual effect Effects 0.000 claims 1
- 230000003287 optical effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 11
- 239000000975 dye Substances 0.000 description 7
- 230000003902 lesion Effects 0.000 description 7
- 230000002685 pulmonary effect Effects 0.000 description 7
- 238000013276 bronchoscopy Methods 0.000 description 5
- 239000008399 tap water Substances 0.000 description 5
- 235000020679 tap water Nutrition 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 4
- 238000001574 biopsy Methods 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 230000003211 malignant effect Effects 0.000 description 4
- 206010056342 Pulmonary mass Diseases 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000013188 needle biopsy Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- 206010000117 Abnormal behaviour Diseases 0.000 description 1
- 206010006272 Breast mass Diseases 0.000 description 1
- 101100172879 Caenorhabditis elegans sec-5 gene Proteins 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 208000009453 Thyroid Nodule Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000011748 cell maturation Effects 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000012631 diagnostic technique Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000004362 fungal culture Methods 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- HSXUHWZMNJHFRV-QIKYXUGXSA-L orange G Chemical compound [Na+].[Na+].OC1=CC=C2C=C(S([O-])(=O)=O)C=C(S([O-])(=O)=O)C2=C1\N=N\C1=CC=CC=C1 HSXUHWZMNJHFRV-QIKYXUGXSA-L 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 238000009595 pap smear Methods 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000002691 topical anesthesia Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 208000010576 undifferentiated carcinoma Diseases 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/30—Staining; Impregnating ; Fixation; Dehydration; Multistep processes for preparing samples of tissue, cell or nucleic acid material and the like for analysis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/30—Staining; Impregnating ; Fixation; Dehydration; Multistep processes for preparing samples of tissue, cell or nucleic acid material and the like for analysis
- G01N2001/305—Fixative compositions
Definitions
- the classic method of preparing a cytologic smear specimen involves staining by the Papanicolaou method. This method is complex and time consuming. A properly prepared specimen according to this method will normally require over one hour to complete. The specimens so obtained exhibit excellent contrast and coloration under microscopic examination and are the standard by which diagnostic cytology is carried out. The use of so-called "modified" Papanicolaou stains allows this time to be reduced by about one-half.
- the elapsed time between obtaining the cytologic smear and the production of the specimen suitably stained for cytologic diagnosis is a definite disadvantage, and it would be extremely useful in the diagnostic field if a method could be devised to permit rapid attainment of stained cytologic specimens whose contrast and coloration were sufficiently identical to that which is obtained by Papanicolaou staining as to allow proper diagnosis by the well-established criteria developed with such latter staining.
- Aspiration biopsy of lesions in selected tissues and organs using a 22 or 23-gauge needle has evolved into a useful and safe technique.
- Thyroid nodules, pancreatic tumors, lung nodules, breast masses and lymph nodes are most commonly biopsied, often resulting in a definitive diagnosis.
- the information gained from this technique is useful in staging neoplasms, directing further diagnostic studies, guiding therapy and rendering prognoses. In some instances, the procedure may obviate further diagnostic studies, resulting in less trauma to the patient and also a definite cost savings.
- the cytologic preparation is adequate in fixation, staining, and cellularity.
- percutaneous lung aspiration In addition to the diagnosis of lung nodules, percutaneous lung aspiration also provides an excellent means of obtaining material for bacterial and fungal cultures as well as the rapid diagnosis of organisms such as Pneumo cytis carinii.
- the invention is directed to the field of cytopathology and, more specifically, to an improved stain and method which allows much more rapid cytological diagnosis of human cells.
- a cell spread specimen may be prepared for microscopic examination within about three minutes and the cells may then be accurately diagnosed with respect to normal and abnormal behavior and functional differentiation to provide requisite diagnosis for various conditions including tumor type.
- the technique of this invention involves the steps of fixing the specimen on the slide, staining the specimen in an alcoholic solution of hematoxylin, hydrating the specimen, staining the specimen in an alcohol-based composite counterstain, hydrating the specimen and then dehydrating, clearing and covering the specimen.
- the staining method typically consumes about three minutes time.
- the composite counterstain allows the elimination of a time-consuming and complex series of staining, hydration and rinsing steps necessary for conventional Papanicolaou staining and is largely responsible for the rapidity with which specimens can be prepared with this invention.
- the composite nature of the counterstain is due not only to the presence therein of a plurality of stain or dye entities but also to the presence of the alcohol base and acids, these composite entities cooperatively producing a rapid and simultaneous uptake of the several stains without detrimental effect or interference among the separate and distinct die components.
- the preferred composite counterstain of this invention is formulated as follows:
- TDC total dye content
- the stains specified are powders having a percent dye content certified by the Biological Stain Commission.
- this dye was obtained as a powder certified to contain 80% dye and 12.5 grams of this powder was dissolved in distilled water up to 100 ml to provide the 10% TDC solution.
- the orange G is identified by registration number of the Chemical Abstract Service, CAS Reg. 1936-15-8 and is listed as Fisher catalog number 0-267, color index 16230.
- the light green SF yellowish, CAS Reg. 5140-20-8 is listed as Fisher catalog number 0-3382, color index 42095.
- the eosin Y, CAS Reg. 17372-87-1 is listed as Fisher catalog number E-510.
- the orange G is present in weight amount of 0.6 gms
- the light green SF yellowish is present in weight amount of 0.6 grams
- the eosin Y is present in weight amount of 4.0 grams, all per liter of the composite counterstain.
- these components may be present in the following ranges:
- the glacial acetic acid may be present in the range of about 10-30 ml/liter and the phosphotungstic acid may be present in the range of about 2-8 grams/liter.
- the absolute methanol and the 95% ethanol components must be present in about the volumes specified above.
- the dips should be effected at the rate of about two per second.
- the above method involving only eleven baths, will ordinarily require only about three minutes for preparation of the specimen for microscopic examination and diagnosis.
- the Gill hematoxylin II listed above is the preferred stain for step 2 and is available from Fisher Scientific Company.
- compositions and method of this invention were developed primarily for use in laboratory screening of fine needle aspirated specimens where rapidity of diagnosis is the principal objective, they are also usable in conjunction with various fluid specimens, Pap smears, skin scrapings, wound touch preps, or any other cytologic cell spreads which are microscopically examined and interpreted on the basis of the known criteria and standards set by the profession.
- the above specified stains as used in the composite counterstain are those which are preferred because they have given the best results and are well known certified stains, it will be appreciated that any acceptable equivalents may be used so long as the concepts of this invention are not violated. That is, the stained specimen must in any event possess contrast and coloration at least closely approximating those characteristics obtained by conventional Papanicolaou staining and the procedure described above must be attainable, i.e., the procedure must be such that the properly stained specimen is obtained within a few minutes and this, in turn, requires a minimum of baths as above noted and the rapidity of dye uptake inherent in the composite counterstain as specified.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Sampling And Sample Adjustment (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
A composite cytologic counterstain formulation and the method of using it are disclosed, the composite counterstain being effective to allow a sequence of staining steps for cytologic specimens which, within a few minutes only, produces a stained specimen having optical contrast and coloration closely approximating that attained by the complex and time-consuming Papanicolaou method.
Description
The classic method of preparing a cytologic smear specimen involves staining by the Papanicolaou method. This method is complex and time consuming. A properly prepared specimen according to this method will normally require over one hour to complete. The specimens so obtained exhibit excellent contrast and coloration under microscopic examination and are the standard by which diagnostic cytology is carried out. The use of so-called "modified" Papanicolaou stains allows this time to be reduced by about one-half.
However, the elapsed time between obtaining the cytologic smear and the production of the specimen suitably stained for cytologic diagnosis is a definite disadvantage, and it would be extremely useful in the diagnostic field if a method could be devised to permit rapid attainment of stained cytologic specimens whose contrast and coloration were sufficiently identical to that which is obtained by Papanicolaou staining as to allow proper diagnosis by the well-established criteria developed with such latter staining.
Aspiration biopsy of lesions in selected tissues and organs using a 22 or 23-gauge needle (thin-needle or fine-needle biopsy) has evolved into a useful and safe technique. Thyroid nodules, pancreatic tumors, lung nodules, breast masses and lymph nodes are most commonly biopsied, often resulting in a definitive diagnosis. The information gained from this technique is useful in staging neoplasms, directing further diagnostic studies, guiding therapy and rendering prognoses. In some instances, the procedure may obviate further diagnostic studies, resulting in less trauma to the patient and also a definite cost savings.
While thin-needle aspiration biopsy has gained in popularity and currently is in widespread use, its success is dependent upon the proper handling and preparation of the aspirated material.
Good cellular preservation is a prerequisite for satisfactory cellular display. The cytologist should be called upon to assist in this technique so as to assure proper fixation and handling of the aspirate. The accuracy with which these small samples of specimen are prepared plays a major role in assessing morpholigic differences between normal and abnormal cells.
Among the benefits of having the cytologist prepare and collect the aspirated specimen are:
1. Abnormal cells are more accurately interpreted.
2. Conclusive diagnosing becomes easier with cells that consistently exhibit abnormalities.
3. Cytomorphology from different observers will agree more closely.
4. Time is saved screening a satisfactory cellular slide.
5. Progress in new areas of cytology will not be underestimated by an unsatisfactory reproduction of the specimen on a slide.
Although aspiration biopsy of pulmonary lesions was first described by Menetrier in 1886, acceptance and popularization of the technique awaited recent technological advances including image intensification and biplanar telefluoroscopy as well as improvements in needle design and the application of CAT scan to the procedure. Most of the modern pioneering work in fine needle aspiration cytology has emanated from the Swedish experience, however, in the past few years we have seen a rapid awakening of interest in aspiration cytology, particularly pulmonary aspiration in this country with a concomitant increase in research and study.
In the proper setting and hands percutaneous lung aspiration is an economical, rapid, safe and accurate method for the diagnosis of pulmonary nodules. In the past, negative sputum and bronchoscopic studies (a rule rather than exception) have led routinely to an open procedure in the diagnosis of such lesions. Although large bore needle biopsies have been available, they have been generally avoided due to their relatively high rates of morbidity. The introduction of fine needle aspiration has added a new dimension to the interpretation of pulmonary masses: A technique combining low morbidity approaching that of bronchoscopy and diagnostic accuracy approaching that of open biopsy. In addition, it is a procedure employing only topical anesthesia which can be performed on an outpatient basis.
Although the clinical pulmonary literature has traditionally referred to bronchoscopy as they key closed chest diagnostic technique, there is growing appreciation of the advantages of fine needle aspiration over this procedure in not only peripheral but also in centrally located lesions. Although the morbidity is slightly higher in aspiration, it is invariably of a minor and transitory nature. In general aspiration is tolerated much better by the patient than bronchoscopy, causing little or no discomfort. Consquently, there is increasing appreciation for and confidence in the procedure and it is often used in increasing proportions of cases in lieu of bronchoscopy in the interpretation of pulmonary nodules. One of the arguments often heard against transthoracic lung aspiration is that it is of limited value since a malignant diagnosis most often necessitates a thoracotomy for diagnosis. Although these statements could be made with some justification for bronchoscopy, a fact which in no way limits the use of that technique, they are not applicable to fine needle aspiration. Not only does this diagnostic modality provide the surgeon with valuable preoperative information, but in many instances makes thoracotomy with its significant risks of morbidity and mortality unnecessary. Instances in which thoracotomy can often be negated are as follows:
1. A malignant diagnosis in a poor surgical risk patient or if a lesion is inoperable for cure.
2. The diagnosis of a pulmonary lesion as metastatic malignancy.
3. The diagnosis of small cell undifferentiated carcinoma.
4. A diagnosis negative for malignancy.
A special note is called for here on the term "negative" as applied to pulmonary aspiration. As opposed to other areas of cytology, "negative" in lung aspiration has very specific criteria and definitions, it does not simply mean the absence of malignant cells on a specimen but rather:
A. The physician performing the aspiration is convinced that the needle was in the lesion in question.
B. The cytologic preparation is adequate in fixation, staining, and cellularity.
C. No malignant cells are present.
D. The cytologic interpretation is consistent with the clinical and radiologic findings.
Only when a specimen meets these criteria should it be signed out as negative. In addition, negative aspirations are usually repeated at least once before the final report is issued. When used in this highly structured way a negative aspiration report can safely be used as the basis for following the patient radiologically at 3, 6 and 12 month intervals rather than intervening surgically. Using negative reports in this manner, the risk of morbidity and mortality due to false negative report is far less than that due to surgery.
In addition to the diagnosis of lung nodules, percutaneous lung aspiration also provides an excellent means of obtaining material for bacterial and fungal cultures as well as the rapid diagnosis of organisms such as Pneumo cytis carinii.
The invention is directed to the field of cytopathology and, more specifically, to an improved stain and method which allows much more rapid cytological diagnosis of human cells. Typically, a cell spread specimen may be prepared for microscopic examination within about three minutes and the cells may then be accurately diagnosed with respect to normal and abnormal behavior and functional differentiation to provide requisite diagnosis for various conditions including tumor type.
Basically, the technique of this invention involves the steps of fixing the specimen on the slide, staining the specimen in an alcoholic solution of hematoxylin, hydrating the specimen, staining the specimen in an alcohol-based composite counterstain, hydrating the specimen and then dehydrating, clearing and covering the specimen. The staining method typically consumes about three minutes time.
The composite counterstain allows the elimination of a time-consuming and complex series of staining, hydration and rinsing steps necessary for conventional Papanicolaou staining and is largely responsible for the rapidity with which specimens can be prepared with this invention. The composite nature of the counterstain is due not only to the presence therein of a plurality of stain or dye entities but also to the presence of the alcohol base and acids, these composite entities cooperatively producing a rapid and simultaneous uptake of the several stains without detrimental effect or interference among the separate and distinct die components.
The preferred composite counterstain of this invention is formulated as follows:
______________________________________ absolute methanol 250 ml 95% ethanol 680 ml glacial acetic acid 20 ml phosphotungstic acid 4 gms. aqueous solution (10% TDC) orange G 6 ml aqueous solution (3% TDC) light 20 ml green SF yellowish aqueous solution (20% TDC) 20 ml eosin Y ______________________________________
In the above composite counterstain, the abbreviation TDC means "total dye content". The stains specified are powders having a percent dye content certified by the Biological Stain Commission. Thus, to prepare the aqueous solution of orange G above, this dye was obtained as a powder certified to contain 80% dye and 12.5 grams of this powder was dissolved in distilled water up to 100 ml to provide the 10% TDC solution.
All stains as used herein should be certified by the Biological Stain Commission and by experimentation it was found that the above powdered certified dyes as obtained from Fisher Scientific Company of Pittsburgh, Pa. gave the best results.
The orange G is identified by registration number of the Chemical Abstract Service, CAS Reg. 1936-15-8 and is listed as Fisher catalog number 0-267, color index 16230. The light green SF yellowish, CAS Reg. 5140-20-8 is listed as Fisher catalog number 0-3382, color index 42095. The eosin Y, CAS Reg. 17372-87-1 is listed as Fisher catalog number E-510.
In the above preferred counterstain, the orange G is present in weight amount of 0.6 gms, the light green SF yellowish is present in weight amount of 0.6 grams and the eosin Y is present in weight amount of 4.0 grams, all per liter of the composite counterstain. However, these components may be present in the following ranges:
______________________________________ orange G 8-18% TDC (0.48-1.08 gm/liter) light green SF yellowish 2-8% TDC (0.4-1.6 gms/liter) eosin Y 10-25% TDC (2-5 gms/liter) ______________________________________
The glacial acetic acid may be present in the range of about 10-30 ml/liter and the phosphotungstic acid may be present in the range of about 2-8 grams/liter.
The absolute methanol and the 95% ethanol components must be present in about the volumes specified above.
To prepare a specimen according to this invention, the following procedure is used, subsequent to application of the cell spread on a microscope slide followed by any accepted method of preserving and fixing the cytologic cell spread thereon (e.g., by use of 95% ethanol or of any commercial water soluble cytologic spray fixative):
______________________________________ Bath time ______________________________________ 1. tap water 5-10 dips (until surface is smooth) 2. Gill's hematoxylin II 30 sec-1 min, including 10 dips initially 3. tap water 5 dips 4. tap water 10 sec 5. composite counterstain 30 sec including 10 dips initially 6. tap water 5 dips 7. tap water 5 dips 8. absolute ethanol 10 dips 9. absolute ethanol 10 dips 10. xylene 5 dips 11. xylene 5 dips, and then coverslip. ______________________________________
The dips should be effected at the rate of about two per second. Thus, the above method, involving only eleven baths, will ordinarily require only about three minutes for preparation of the specimen for microscopic examination and diagnosis.
The Gill hematoxylin II listed above is the preferred stain for step 2 and is available from Fisher Scientific Company.
Although the composition and method of this invention were developed primarily for use in laboratory screening of fine needle aspirated specimens where rapidity of diagnosis is the principal objective, they are also usable in conjunction with various fluid specimens, Pap smears, skin scrapings, wound touch preps, or any other cytologic cell spreads which are microscopically examined and interpreted on the basis of the known criteria and standards set by the profession.
Although the above specified stains as used in the composite counterstain are those which are preferred because they have given the best results and are well known certified stains, it will be appreciated that any acceptable equivalents may be used so long as the concepts of this invention are not violated. That is, the stained specimen must in any event possess contrast and coloration at least closely approximating those characteristics obtained by conventional Papanicolaou staining and the procedure described above must be attainable, i.e., the procedure must be such that the properly stained specimen is obtained within a few minutes and this, in turn, requires a minimum of baths as above noted and the rapidity of dye uptake inherent in the composite counterstain as specified.
Claims (3)
1. A method of rapid cytological diagnosis of human cells comprising the steps of
(a) fixing a specimen on a slide,
(b) staining the specimen in a solution of hematoxylin,
(c) hydrating the specimen, and thereafter,
(d) staining the specimen in a composite cytologic counterstain for obtaining within a few minutes a specimen which when examined by a microscope provides a visual image exhibiting contrast and coloration comparable to that obtained by Papanicolaou method of staining, which consists essentially of
6 ml of an aqueous solution of about 8-18% total dye content of orange G, 20 ml of an aqueous solution of about 2-8% total dye content of light green SF yellowish, 20 ml of an aqueous solution of about 10-25% total dye content of eosin Y, from 20-30 ml of glacial acetic acid, from 2-8 grams of phosphotungstic acid, and the balance, to make one liter, of a mixture of methyl and ethyl alcohols.
2. The method as defined in claim 1 wherein the methyl alcohol is absolute and is present in the amount of 2.50 ml and the ethyl alcohol is 95% ethyl alcohol present in amount of 680 ml.
3. The method as defined in claim 1 wherein the aqueous orange G is present as a 10% total dye content aqueous solution, the light green SF yellowish is present as a 3% total dye content aqueous solution; and the eosin Y is present as a 20% total dye content aqueous solution.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US06/429,662 US4550016A (en) | 1982-09-30 | 1982-09-30 | Composite cytologic counterstain formulation |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US06/429,662 US4550016A (en) | 1982-09-30 | 1982-09-30 | Composite cytologic counterstain formulation |
Publications (1)
Publication Number | Publication Date |
---|---|
US4550016A true US4550016A (en) | 1985-10-29 |
Family
ID=23704205
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US06/429,662 Expired - Fee Related US4550016A (en) | 1982-09-30 | 1982-09-30 | Composite cytologic counterstain formulation |
Country Status (1)
Country | Link |
---|---|
US (1) | US4550016A (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6143512A (en) * | 1998-08-17 | 2000-11-07 | Markovic; Nenad | Cap-pap test |
WO2001033192A1 (en) * | 1999-10-29 | 2001-05-10 | Cytyc Corporation | Cytological stain composition |
US6284543B1 (en) * | 2000-08-08 | 2001-09-04 | Iliana I. Alvarez | Rapid papanicolaou staining method for cervico-vaginal specimens |
KR20020006883A (en) * | 2000-07-14 | 2002-01-26 | 이수빈 | Cyto-Quik stain solution |
US6348325B1 (en) | 1999-10-29 | 2002-02-19 | Cytyc Corporation | Cytological stain composition |
GB2372811A (en) * | 2001-02-14 | 2002-09-04 | Hector Cairns | Staining physiological samples |
US6593102B2 (en) | 1999-10-29 | 2003-07-15 | Cytyc Corporation | Cytological stain composition |
CN108195653A (en) * | 2017-09-16 | 2018-06-22 | 南京福怡科技发展股份有限公司 | One kind redyes staining kit and preparation and application |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3440317A (en) * | 1964-11-09 | 1969-04-22 | Arfilio J Martinez | Cell coloring process and composition for cytological examination |
-
1982
- 1982-09-30 US US06/429,662 patent/US4550016A/en not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3440317A (en) * | 1964-11-09 | 1969-04-22 | Arfilio J Martinez | Cell coloring process and composition for cytological examination |
Non-Patent Citations (4)
Title |
---|
Clark (Ed.), Staining Procedures , 4th Ed. Williams and Wilkins, London 1981, pp. 208 209. * |
Clark (Ed.), Staining Procedures, 4th Ed. Williams and Wilkins, London 1981, pp. 208-209. |
Lillie, R. D., Histopathologic Technic and Practical Histochemistry , 3rd Ed., McGraw Hill, N.Y., 1965, pp. 561 565. * |
Lillie, R. D., Histopathologic Technic and Practical Histochemistry, 3rd Ed., McGraw-Hill, N.Y., 1965, pp. 561-565. |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6143512A (en) * | 1998-08-17 | 2000-11-07 | Markovic; Nenad | Cap-pap test |
WO2001033192A1 (en) * | 1999-10-29 | 2001-05-10 | Cytyc Corporation | Cytological stain composition |
US6348325B1 (en) | 1999-10-29 | 2002-02-19 | Cytyc Corporation | Cytological stain composition |
US6593102B2 (en) | 1999-10-29 | 2003-07-15 | Cytyc Corporation | Cytological stain composition |
KR20020006883A (en) * | 2000-07-14 | 2002-01-26 | 이수빈 | Cyto-Quik stain solution |
US6284543B1 (en) * | 2000-08-08 | 2001-09-04 | Iliana I. Alvarez | Rapid papanicolaou staining method for cervico-vaginal specimens |
WO2002012881A1 (en) * | 2000-08-08 | 2002-02-14 | Alvarez Iliana I | Rapid papanicolaou staining method for cervico-vaginal specimens |
GB2372811A (en) * | 2001-02-14 | 2002-09-04 | Hector Cairns | Staining physiological samples |
GB2372811B (en) * | 2001-02-14 | 2005-01-26 | Hector Cairns | Stain |
CN108195653A (en) * | 2017-09-16 | 2018-06-22 | 南京福怡科技发展股份有限公司 | One kind redyes staining kit and preparation and application |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Mavec et al. | Aspiration biopsy of salivary gland tumours: I. Correlation of cytologic reports from 652 aspiration biopsies with clinical and histologic findings | |
Ayre | Selective cytology smear for diagnosis of cancer | |
Dixon et al. | The morphological basis of human breast cyst populations | |
Payne et al. | Diagnostic accuracy of cytology and biopsy in primary bronchial carcinoma. | |
CN113383769B (en) | Cell preservation solution and preparation method and application thereof | |
US4550016A (en) | Composite cytologic counterstain formulation | |
Hahn et al. | Cytopathologic touch preparations (imprints) from core needle biopsies: accuracy compared with that of fine-needle aspirates. | |
Japa | A study of the mitotic activity of normal human bone marrow | |
Auer et al. | Comparison of DNA distributions in primary human breast cancers and their metastases | |
CN113504091A (en) | Accurate-identification and stable fungus fluorescent staining solution | |
Scopa et al. | Sources of diagnostic discrepancies in fine‐needle aspiration of the breast | |
Sonta et al. | Chromosomes and causation of human cancer and leukemia XXX. Banding studies of primary intestinal tumors | |
Martins | Leaf and calycine colleters in Odontadenia lutea (Apocynaceae-Apocynoideae-Odontadenieae): their structure and histochemistry | |
Lukacs et al. | Cytofluorimetric measurements on the DNA contents of tumors cells in human thyroid gland | |
Reid et al. | Deoxyribonucleic acid values (Feulgen microspectrophotometry) in epithelium of human ectocervix, normal and cancerous | |
Ishii et al. | Criteria for differential diagnosis of complex hyperplasia or beyond in endometrial cytology | |
Das et al. | Liquid-based vs. conventional smears in fine needle aspiration of bone and soft tissue tumors | |
Bishop et al. | A study of transrectal aspiration biopsies of the prostate, with particular regard to prognostic evaluation | |
Pellegrino et al. | Differential expression of keratins 13 and 16 in normal epithelium, benign lesions, and ductal carcinomas of the human breast determined by the monoclonal antibody Ks8. 12 | |
SUSSMAN | Detection of gynecologic cancer by fluorescence microscopy | |
Von Bertalanffy et al. | DETECTION OF GYNECOLOGICAL CANCER—Use of Fluorescence Microscopy to Show Nucleic Acids in Malignant Growth | |
Madeleine et al. | Fine‐needle cytology of an eccrine spiradenoma of the breast: Diagnosis made by a holistic approach | |
Cosgrove et al. | Diagnosis of pulmonary blastoma by fine‐needle aspiration biopsy: Cytologic and immunocytochemical findings | |
Hofstädter et al. | Cytophotometric investigations of DNA-content in transitional cell tumors of the bladder comparison of results with clinical follow up | |
Zare-Mirzaie et al. | Rehydration of air-dried cervical smears: an alternative to routine wet fixation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
REMI | Maintenance fee reminder mailed | ||
LAPS | Lapse for failure to pay maintenance fees | ||
STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
|
FP | Lapsed due to failure to pay maintenance fee |
Effective date: 19891029 |